Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Orforglipron vs Survodutide: Orforglipron has the stronger overall evidence (5.5 vs 5.5/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Orforglipron wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Orforglipron and Survodutide have evidence — compare verdict strength side-by-side.
INVESTIGATIONAL — no approved consumer dose. In trials, once-daily oral orforglipron was titrated up to 36 mg (some phase-2 cohorts to 45 mg) with gradual dose escalation to limit GI side effects. Not for self-administration; only appropriate within a clinical trial or, if/when approved, under a prescribing clinician.
any
Oral tablet (investigational)
Investigational — NO approved dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation up to 4.8-6.0 mg maintenance. There is no approved regimen; do not self-dose an unapproved drug.
once-weekly
Once-weekly subcutaneous injection (investigational only)
Weeks to months
Months (titrated)
Throughout use
Especially during dose escalation
Progressive over 24-46 weeks
By 48 weeks
By 16-46 weeks
Especially during dose escalation
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1).
N Engl J Med (2025) · Rct · n=3127
Phase-3 multinational double-blind RCT in 3,127 adults with obesity WITHOUT diabetes; once-daily oral orforglipron 6/12/36 mg vs placebo for 72 weeks
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1).
N Engl J Med (2025) · Rct · n=559
Phase-3 double-blind RCT in 559 adults with early type 2 diabetes managed by diet/exercise; once-daily oral orforglipron 3/12/36 mg vs placebo for 40 weeks
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
Lancet (2026) · Rct · n=962
Phase-3 non-inferiority RCT (n=962) in type 2 diabetes inadequately controlled on metformin; once-daily oral orforglipron 3/12/36 mg vs dapagliflozin 10 mg over 40 weeks
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
N Engl J Med (2024) · Rct · n=293
48-week phase-2, double-blind, randomized, placebo-controlled trial in 293 adults with biopsy-confirmed MASH and fibrosis stage F1-F3, once-weekly subcutaneous survodutide 2.4/4.8/6.0 mg vs placebo with a 24-week rapid-escalation then 24-week maintenance design
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
Lancet Diabetes Endocrinol (2024) · Rct · n=387
Phase-2, double-blind, randomized, placebo-controlled dose-finding trial in 387 adults with obesity (BMI ≥27) across 43 centres in 12 countries, once-weekly subcutaneous survodutide 0.6-4.8 mg vs placebo for 46 weeks
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Diabetologia (2024) · Rct · n=413
Phase-2, multicentre, double-blind, randomized, placebo-controlled dose-response trial in 413 adults with type 2 diabetes, once-weekly subcutaneous survodutide across six dose groups vs placebo, with an open-label semaglutide reference arm
Orforglipron has a higher evidence score (5.5/10 vs 5.5/10) and wins in 1 of 3 categories.
For manage blood sugar, Orforglipron has a higher relevance score (70 vs 48).
No known interactions between Orforglipron and Survodutide have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.